Abbott Q1 Diagnostic Revenues Drop 2 Percent Despite Slight Uptick in MDx Sales | GenomeWeb

NEW YORK (GenomeWeb) – Abbott reported on Wednesday morning that its first quarter diagnostic revenues decreased around 2 percent year over year, although its molecular diagnostic sales inched up a fraction of a percent.

The Abbott Park, Ill.-based company reported total worldwide revenues of $4.90 billion for the three months ended March 31, up 3 percent from $4.76 billion a year ago and surpassing analysts' consensus estimate of $4.85 billion. Excluding negative currency effects, total sales increased 10 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.